Ulcerative Colitis

Subscribe to Selected New Research on Ulcerative Colitis

8027 relevant articles (827 outcomes, 1119 trials/studies) found for this Disease

Description: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.

Also Known As:

Colitis, Ulcerative

Relationship Network

Disease Context: Research Results

Digestive System Diseases: 31

Gastrointestinal Diseases: 1230

Gastroenteritis: 1813

Inflammatory Bowel Diseases: 6504

Ulcerative Colitis: 8027

Colitis: 5811

Ulcerative Colitis: 8027

Intestinal Diseases: 601

Inflammatory Bowel Diseases: 6504

Ulcerative Colitis: 8027

Colonic Diseases: 184

Colitis: 5811

Ulcerative Colitis: 8027

Related Diseases

1.	Crohn Disease (Crohn's Disease)
2.	Colitis
3.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
4.	Proctitis
5.	Inflammation

Experts

1.	Sandborn, William J: 18 articles (08/2008 - 07/2002)
2.	Ouyang, Qin: 13 articles (01/2008 - 06/2003)
3.	Sandborn, W J: 12 articles (07/2008 - 12/2000)
4.	Rutgeerts, Paul: 10 articles (04/2007 - 02/2003)
5.	Hibi, Toshifumi: 9 articles (08/2008 - 01/2002)
6.	Lichtenstein, Gary R: 9 articles (03/2008 - 10/2002)
7.	Takeuchi, Ken: 9 articles (12/2006 - 10/2002)
8.	Hanai, Hiroyuki: 9 articles (12/2006 - 10/2002)
9.	Iida, Takayuki: 9 articles (12/2006 - 10/2002)
10.	Rutgeerts, P: 9 articles (11/2006 - 02/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ulcerative Colitis:

1.	Mesalamine (Mesalazine)FDA LinkGeneric 01/01/2007 - "* In a well designed phase III trial in patients with active, mild to moderate ulcerative colitis (n = 262), significantly (p < 0.01) more MMX mesalazine 2.4 (34%) or 4.8 g/day (29%) recipients than placebo recipients (13%) achieved clinical and endoscopic remission after 8 weeks of treatment.* In a second phase III trial (n = 341), clinical and endoscopic remission rates with MMX mesalazine 2.4 (40.5%) and 4.8 g/day (41.2%) were significantly (p < 0.01) greater than with placebo (22.1%) after 8 weeks, while the remission rate with non-MMX delayed-release mesalazine (Asacol) [32.6%] did not differ from placebo.* Overall, MMX mesalazine was generally well tolerated in controlled clinical trials, with a similar incidence of treatment-emergent adverse events in placebo (66%) and MMX mesalazine (56%) recipients in a pooled analysis; most adverse events were of mild or moderate severity. " 09/21/2009 - "5-Aminosalicylic acid (5-ASA) compounds are a highly effective treatment for ulcerative colitis (UC). " 07/01/2007 - "5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcerative colitis, a chronic inflammatory condition that most commonly affects the distal part of the colon. " 01/01/2006 - "The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. " 05/01/1991 - "Topical mesalazine has proved extremely effective in patients with distal ulcerative colitis; oral forms are effective in the treatment of mild to moderately active ulcerative colitis and in relapse. " Order ALL the reference details at left...
2.	Sulfasalazine (Azulfidine)FDA LinkGeneric 12/01/1985 - "Sulfasalazine is of proven efficacy as maintenance therapy in ulcerative colitis. " 09/01/1990 - "Since the development of sulfasalazine about a half century ago, the prognosis for patients with ulcerative colitis has improved significantly. " 04/01/1985 - "In the case of sulphasalazine, adult slow acetylators require a lower daily dose of the drug than fast acetylators in order to maintain ulcerative colitis in remission without significant side effects. " 06/10/1978 - "Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fibre diet: a clinical trial." 08/01/1985 - "The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. " Order ALL the reference details at left...
3.	infliximab (Remicade)FDA Link 09/20/2009 - "Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. " 06/01/2007 - "Infliximab also has proven to be efficacious in patients with ulcerative colitis (UC) and has increased rates of steroid-free remission. " 06/01/2006 - "[Infliximab in active ulcerative colitis -- proven efficacy as induction and maintenance treatment]" 08/01/2001 - "Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis." 06/01/2006 - "Two recent trials, Active Ulcerative Colitis Trial (ACT) 1 and ACT 2, observed high efficacy of infliximab in inducting and maintaining clinical remission, mucosal healing, and corticosteroid-sparing effects in patients with moderate to severe UC. " Order ALL the reference details at left...
4.	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/01/2003 - "BACKGROUND AND AIMS: Cyclosporine A is highly effective in severe attacks of ulcerative colitis (UC) but is associated with important adverse effects that are mainly dose dependent. " 11/01/2008 - "BACKGROUND: Cyclosporine A (CsA) has been found to be the first successful therapy used in the recovery of patients with steroid-refractory ulcerative colitis (UC). " 09/04/1998 - "Our data confirm the efficacy of intravenous cyclosporine as a rapid acting drug for severe ulcerative colitis. " 04/01/1993 - "Treatment with the immunosuppressive agent cyclosporine proved beneficial in the child leading to remission of the ulcerative colitis and nascent growth of scalp and body hair." 01/01/2005 - "AUTHORS' CONCLUSIONS: There is limited evidence that cyclosporine is more effective than standard treatment alone for severe ulcerative colitis. " Order ALL the reference details at left...
5.	Adrenal Cortex Hormones (Corticosteroids)IBA 09/28/2008 - "Corticosteroids are still the first-line treatment for active ulcerative colitis more than 50 years after the publication of trials assessing their beneficial effect, with about a 50% remission rate in cases of severe disease. " 06/01/2006 - "Centrifugal leukocytapheresis without corticosteroid treatment can induce remission in patients with active ulcerative colitis, and might be particularly beneficial for patients in whom adverse effects preclude the use of corticosteroids." 05/01/1998 - "Therapy with high-dose corticosteroids led to healing of the skin and upper eyelid lesions and induced remission of ulcerative colitis." 07/01/2000 - "Meta-analyses of published trials show that rectally delivered 5-ASA is superior to placebo and to conventional rectal corticosteroids in inducing remission of distal ulcerative colitis, whereas the combination of rectal 5-ASA with a rectal corticosteroid or oral aminosalicylate is superior to rectal 5-ASA alone. " 06/01/1997 - "CONCLUSIONS: Rectal 5-ASA is superior to rectal corticosteroids in the management of distal ulcerative colitis." Order ALL the reference details at left...
6.	Azathioprine (Imuran)FDA LinkGeneric 01/01/2002 - "The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis." 07/04/1992 - "CONCLUSIONS--Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug. " 05/22/2004 - "OBJECTIVE: To know whether the therapeutic protocol applied in the case of severe acute ulcerative colitis (UC) associating ciclosporine and azathioprine was also effective in the case of moderate chronic active ulcerative colitis (UC). " 10/01/2002 - "CONCLUSIONS: Azathioprine is effective in patients with steroid-dependent or steroid-resistant ulcerative colitis. " 01/01/2003 - "Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis." Order ALL the reference details at left...
7.	SteroidsIBA 09/28/2008 - "Although systemic steroids are highly efficacious in ulcerative colitis (UC), failure to respond to steroids still poses an important challenge to the surgeon and physician alike. " 11/01/1999 - "Despite its intermittent course of activity and remission, the good response to salazopyridine and steroids makes the long-term prognosis of ulcerative colitis favorable. " 07/01/1995 - "Sixty percent (18/30) of severe ulcerative colitis were in remission after mean duration of 9.2 days (range 2-20 days) of intensive intravenous therapy without major side effects of steroids. " 05/01/2008 - "CONCLUSIONS: Intravenous CsA is effective in inducing remission of ulcerative colitis in severe attacks resistant to i.v. steroids. " 10/01/2004 - "In ulcerative colitis, steroids are rarely needed as 5-aminosalicylates are effective in the majority of patients. " Order ALL the reference details at left...
8.	olsalazine (Dipentum)FDA Link 09/01/1994 - "The optimal dose of olsalazine for maintaining remission in ulcerative colitis is 1 g/day. " 09/01/1994 - "To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. " 06/01/1992 - "Olsalazine is also effective in the maintenance of remission of ulcerative colitis. " 04/01/1986 - "Azodisal sodium appears to be an effective agent for the maintenance treatment of ulcerative colitis." 09/01/1994 - "Optimum dose of olsalazine for maintaining remission in ulcerative colitis." Order ALL the reference details at left...
9.	balsalazide (Colazal)FDA LinkGeneric 08/01/1992 - "It is concluded that balsalazide is a well-tolerated drug, and is effective for the maintenance of remission in patients with ulcerative colitis, the optimal dose being greater than 2 g daily." 02/15/2004 - "CONCLUSIONS: Long-term, patient-led, maintenance treatment with balsalazide is well tolerated with a good safety profile and is effective for patients with ulcerative colitis." 11/01/2004 - "BACKGROUND: Balsalazide is well tolerated and effective in treating acute ulcerative colitis. " 06/01/2002 - "Balsalazide has been shown previously to be well tolerated and effective in the treatment of acute ulcerative colitis. " 02/01/1997 - "These results suggest that BX661A may be clinically effective and useful in the treatment of patients with ulcerative colitis. " Order ALL the reference details at left...
10.	Nicotine FDA Link 04/01/1997 - "The most recent clinical trials on the use of nicotine in the management of ulcerative colitis have suggested that nicotine, in combination with conventional pharmacologic therapy, may result in clinical improvement in some patients. " 04/13/1995 - "Transdermal nicotine alone was no better than placebo in the maintenance of remission of ulcerative colitis, and premature withdrawal due to side effects was more common in the nicotine group." 02/01/1998 - "I've heard that the nicotine skin patch is a new treatment for ulcerative colitis. " 05/01/1999 - "Controlled trials have demonstrated efficacy of transdermal nicotine for active ulcerative colitis. " 11/01/1999 - "Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study." Order ALL the reference details at left...

Therapies and Procedures

1.	Enema (Enemas) 04/20/1993 - "5-ASA enemas are very effective in the treatment of distal ulcerative colitis. " 06/01/1986 - "We conclude that in patients with distal ulcerative colitis unresponsive to standard therapy, treatment with 5-ASA enemas results in significant short-term clinical and sigmoidoscopic improvement in a majority of cases. " 09/01/2005 - "OBJECTIVE: To explore the therapeutic efficacy of patients with ulcerative colitis (UC) treated by retention enema and per-colonoscopic spraying of Zhikang Compound Liquid (ZKCL). " 01/01/1998 - "Are short-chain fatty acid enemas effective for left-sided ulcerative colitis?" 06/01/1995 - "BACKGROUND: Some evidence indicates that short-chain fatty acid (SCFA) enemas are effective in the treatment of distal ulcerative colitis. " Order ALL the reference details at left...
2.	Colectomy 09/01/2006 - "Our findings may help to predict patients with ulcerative colitis who have a high risk for colectomy." 04/01/1975 - "Colectomy is more effective than high-dose steroid therapy in reversing the growth retardation caused by ulcerative colitis and is of greatest value if not delayed too long. " 10/01/1995 - "CONCLUSIONS: This study suggests that AI will be useful in evaluation of response to medical therapy and prediction of remission and colectomy in patients with moderately active ulcerative colitis." 01/01/2009 - "A meta-analysis partially confirms previous findings that smoking was found to be protective against ulcerative colitis and, after the onset of the disease, might improve its course, decreasing the need for colectomy. " 12/14/2007 - "A recent meta-analysis partially confirmed previous findings that smoking was found to be protective against ulcerative colitis and, after onset of the disease, might improve its course, decreasing the need for colectomy. " Order ALL the reference details at left...
3.	Blood Component Removal (Apheresis) 11/28/2005 - "Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis." 02/01/2009 - "Leukocytapheresis is effective for ulcerative colitis (UC), and both peripheral leukocyte and platelet counts decrease during apheresis. " 01/01/2008 - "BACKGROUND: Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). " 10/01/2002 - "Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis." 05/01/1998 - "We have already reported that leukocyte apheresis using a centrifugal procedure was effective for patients with corticosteroid-resistant ulcerative colitis after conducting a pilot study in 14 patients. " Order ALL the reference details at left...
4.	Remission Induction 01/01/2007 - "OBJECTIVES: This review evaluates the efficacy of fish oil for induction of remission in ulcerative colitis using all available randomised controlled trials. " 01/01/2009 - "SELECTION CRITERIA: Randomized controlled trials comparing MLN-02 to placebo or a control therapy for the induction of remission in ulcerative colitis were included. " 01/01/2008 - "This trial suggests a potential benefit over placebo for both achieving clinical response and induction of remission in patients with active ulcerative colitis without apparent toxicity." 01/01/2007 - "SELECTION CRITERIA: Randomised controlled trials investigating the effectiveness of probiotics compared to standard treatments in the induction of remission of active ulcerative colitis DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data for analysis. " 01/01/2009 - "OBJECTIVES: To determine the efficacy and safety of MLN-02 for induction of remission in ulcerative colitis. " Order ALL the reference details at left...
5.	Restorative Proctocolectomy 06/01/2001 - "Restorative proctocolectomy has dramatically improved the treatment of familial polyposis and ulcerative colitis with rectal involvement. " 11/14/2007 - "While restorative proctocolectomy with ileal pouch-anal anastomosis has significantly improved the quality of life in patients with underlying ulcerative colitis who require surgery, complications can occur. " 07/01/1993 - "Restorative proctocolectomy is a major advance in the management of ulcerative colitis." 03/01/2004 - "Restorative proctocolectomy is the gold standard for patients with ulcerative colitis who are suitable for surgical treatment, though future prospective trials are needed in order to establish when elective surgery for ulcerative colitis is indicated." 11/01/2005 - "PURPOSE: Restorative Proctocolectomy and Ileal Pouch Anal Anastomosis has become the gold standard surgical therapy for the majority of patients with mucosal ulcerative colitis. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Ulcerative Colitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 827 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>